ADC Offers Promising Results in Relapsed or Refractory Hodgkin Lymphoma
Investigational camidanlumab tesirine led to a high response rate in heavily pretreated patients with relapsed or refractory…
Browsing Tag
ADC
CytomX Therapeutics Presents Overview of Conditionally-Activated Antibody-Drug…
- Presentation at World ADC Conference in San Diego - - CX-2051 integrates CytomX core platform expertise to potentially maximize therapeutic window - SOUTH SAN FRANCISCO, Calif., Sept.…
Tonix Pharmaceuticals Announces Ribbon-Cutting Ceremony for its Advanced Development…
The ADC is Expected to Accelerate Clinical-Scale Manufacturing of Live Virus Vaccines, Including Vaccines for Monkeypox, Smallpox and COVID-19 Internal Manufacturing Capabilities Expected…
Novel ADC Promising in Tough-to-Treat Ovarian Cancer
PHOENIX -- Mirvetuximab soravtansine monotherapy demonstrated anti-tumor activity in previously treated patients with folate…
Trastuzumab ADC Active in HER2-Low, HER2-Undetected Breast Cancer
SAN ANTONIO -- A headline-making antibody-drug conjugate (ADC) continued to impress breast cancer specialists by demonstrating…
TROP2-Directed ADC Promising in Advanced Triple-Negative Breast Cancer
SAN ANTONIO -- The investigational agent datopotamab deruxtecan (Dato-DXd) offered antitumor activity with a manageable safety…
Sorrento Receives FDA Clearance to Proceed With Clinical Trial for Anti-TROP-2…
Anti-TROP-2 ADC with a drug payload SN38 (a DNA polymerase inhibitor) (ESG-401) has received FDA authorization to begin clinical trials in the US.ESG-401 addresses a highly unmet need for…
Araris Biotech AG to Present at 12th Annual World ADC Digital Conference
ZURICH, Switzerland, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Araris Biotech AG, a company pioneering a proprietary antibody-drug conjugate (ADC)-linker technology, announced that data from its…
Enstar Completes ADC Agreement With RSA
HAMILTON, Bermuda, Oct. 06, 2021 (GLOBE NEWSWIRE) -- Enstar Group Limited (NASDAQ: ESGR) announced today that one of its wholly owned subsidiaries has closed a previously announced…
ADC Combined With Immunomodulators Active in R/R Myeloma
Indatuximab ravtansine (BT062) combined with immunomodulatory drugs showed antitumor activity…